peptides for testosterone FAQ

Verify that your pituitary gonadotrophs are responsive by checking baseline LH and FSH levels. If both are suppressed and don't respond to exogenous GnRH (gonadorelin challenge test), the problem is pituitary, not hypothalamic. Kisspeptin stimulates GnRH neurons, but if downstream signaling is impaired by pituitary adenoma, prior steroid use, or genetic gonadotropin deficiency, no amount of GnRH stimulation will produce LH. In such cases, hCG is the only peptide that bypasses the pituitary entirely.

Exogenous testosterone suppresses the HPG axis via negative feedback at the hypothalamus and pituitary. Introducing more GnRH or kisspeptin won't overcome that suppression while exogenous androgens are present. hCG can stimulate testicular Leydig cells directly, preserving intratesticular testosterone and preventing testicular atrophy during TRT, but it does not restore pituitary LH secretion. Full HPG axis recovery requires discontinuing exogenous testosterone and using a post-cycle therapy protocol (typically hCG + selective estrogen receptor modulators) to reactivate upstream signaling.

Peptides stored above 8°C for more than 4–6 hours undergo irreversible conformational changes. The amino acid chains denature, rendering the peptide biologically inactive. There's no visual indicator of degradation. The solution remains clear. If a vial was left at room temperature overnight, discard it. Lyophilized (powder) peptides tolerate brief ambient temperature exposure (up to 25°C for 24–48 hours), but once reconstituted with bacteriostatic water, the stability window collapses to 28 days under refrigeration.

Start HCG at 500 IU three times weekly and expect gradual recovery over 12–18 months, not weeks. Testicular volume may increase 10–15% within the first three months, but full recovery to baseline is uncommon once atrophy exceeds 30%. A 2021 study from the University of Utah found that men who added HCG after 12+ months of testosterone monotherapy regained an average of 8% testicular volume after 24 months of HCG use. Significant but not complete reversal. If fertility is the goal, add recombinant FSH (75–150 IU three times weekly) alongside HCG to accelerate spermatogenic recovery.

Reduce the HCG dose first. Estradiol elevation on HCG is dose-dependent. Intratesticular testosterone is aromatised locally, and HCG doses above 500 IU per injection drive excessive conversion. Drop to 250 IU every other day and retest estradiol in four weeks. If estradiol remains >50 pg/mL after dose reduction, a low-dose aromatase inhibitor (0.25–0.5mg anastrozole twice weekly) can be added, but our experience shows most cases resolve with HCG dose adjustment alone. Over-suppressing estradiol (<20 pg/mL) negatively affects lipid profiles, bone density, and mood. Aromatase inhibitors should be the last adjustment, not the first.

HCG alone preserves fertility in 50–65% of men on TRT, which is better than the 8% success rate with testosterone monotherapy. Adding recombinant FSH (not a peptide, but mechanistically necessary for spermatogenesis) increases that figure to 75–80%. The protocol: HCG 250 IU every other day + FSH 75 IU three times weekly. Monitor semen analysis every 12 weeks. If sperm count remains above 5 million/mL, the protocol is working. If counts drop below 1 million/mL after six months, consider stopping testosterone entirely and switching to enclomiphene monotherapy (12.5–25mg daily), which maintains testosterone while preserving endogenous production.

MK-677 is the only growth hormone secretagogue with meaningful oral bioavailability. Peptides like CJC-1295 and ipamorelin are degraded by gastric enzymes before reaching systemic circulation. Research comparing subcutaneous ipamorelin to oral administration found zero detectable GH elevation with oral dosing, even at 10× the subcutaneous dose. For protocols where injections are not feasible, MK-677 at 25mg daily is the mechanistically appropriate alternative, though the continuous GH release pattern differs from the pulsatile secretion produced by injectable peptides.

Discard immediately. Cloudiness indicates either bacterial contamination or protein aggregation, both of which render the peptide inactive and potentially unsafe for research use. Proper reconstitution with bacteriostatic water should produce a clear, colourless solution. Aggregation occurs when peptides are exposed to excessive shaking, temperature fluctuations above 8°C, or low-quality diluent with incorrect pH. The protocol that eliminates this: reconstitute by gently rolling the vial rather than shaking, store at 2–8°C immediately, and use pharmaceutical-grade bacteriostatic water with pH 6.0–7.0.

Verify HPG axis baseline function first. If endogenous LH is already suppressed due to prior exogenous androgen use or hypothalamic hypogonadism, GH secretagogues may amplify pulsatile signalling but cannot overcome primary axis dysfunction. Research published in Andrology found that men with baseline LH below 1.5 IU/L showed minimal testosterone response to ipamorelin after 8 weeks, suggesting that the limiting factor was pituitary LH reserve rather than GH signalling. In these cases, combining a GH secretagogue with hCG (human chorionic gonadotropin). Which directly mimics LH. May restore axis function where GH modulation alone cannot.

Yes, but the mechanism changes. Exogenous testosterone suppresses your natural LH and FSH production, so peptides targeting the HPG axis (like kisspeptin) won't restore endogenous production while you're on TRT. Growth hormone secretagogues like MK 677 and CJC-1295 still work because they act through GH/IGF-1, not the testosterone axis. Men on TRT who add MK 677 report improved body composition, sleep quality, and recovery. Benefits driven by elevated GH rather than further testosterone increases.

Stacking a GHRH analog (CJC-1295 with DAC, 2mg weekly) with a GHRP (GHRP-2, 100mcg 2× daily) produces synergistic GH release because the two pathways don't compete. GHRH provides the release signal while GHRP blocks somatostatin inhibition. Research in Clinical Endocrinology shows this combination raises IGF-1 2–3× more than either peptide alone. Adding MK 677 on top of injectable peptides is redundant and increases side effects (water retention, elevated fasting glucose) without proportional benefit. Choose injectable stack or oral secretagogue, not both simultaneously.

Retest injection timing first. Administering peptides during the body's natural GH suppression window (mid-morning to early afternoon) reduces effectiveness by 50–70%. Switch all doses to within 30 minutes of sleep onset or immediately upon waking. If timing is correct, the limiting factor is likely inadequate sleep (fewer than seven hours nightly suppresses GH release regardless of peptide dose) or chronic caloric deficit, which downregulates the HPG axis independently of GH stimulation. Peptides amplify existing hormonal signaling. They can't override metabolic suppression.

Discard it. A peptide left at room temperature (20–25°C) for more than 6–8 hours has undergone partial denaturation. The protein's tertiary structure has been compromised. You can't tell by looking at it, and attempting to use it risks injecting an inactive or partially active compound. The cost of replacing one vial is far lower than the wasted time and effort of continuing a protocol with degraded material.

First, verify your reconstitution and storage methods. Most 'non-responders' had preparation errors. Second, confirm baseline testosterone and IGF-1 levels with bloodwork. If your IGF-1 hasn't increased, the peptide isn't working (whether due to product quality, dosing error, or individual non-response). Third, assess lifestyle factors: inadequate sleep, chronic caloric deficit, or overtraining all suppress the HPG axis and can blunt peptide effects. If all three check out and you're still a non-responder, consider switching peptides or consulting an endocrinologist to rule out primary hypogonadism.

GHRPs require consistent daily dosing to maintain elevated GH. Missing two consecutive days drops IGF-1 back toward baseline within 48 hours. CJC-1295 with DAC is more forgiving due to its 6–8 day half-life; missing one weekly injection delays progress but doesn't reset it entirely. MK 677 has a 24-hour half-life, so skipping a single dose reduces that day's GH output but resumes normal effect the next day. The bigger issue is circadian misalignment: injecting at random times (sometimes morning, sometimes evening) trains the pituitary to expect GH signals at inconsistent intervals, blunting overall responsiveness over weeks.

Switch to kisspeptin-10 or verify pulsatile dosing frequency—continuous gonadorelin exposure (daily bolus instead of 90-minute pulses) causes GnRH receptor desensitization within 7–10 days, which suppresses LH secretion rather than stimulating it. The pituitary adapts to sustained GnRH signaling by downregulating receptor density—a protective mechanism against overstimulation. If pulsatile administration is confirmed and LH remains flat, the issue is likely upstream (hypothalamic dysfunction) or downstream (primary hypogonadism where Leydig cells can't respond to LH). Kisspeptin acts earlier in the cascade and may bypass pituitary-level resistance.

Reduce the dose to 12.5 mg daily or switch to hexarelin with twice-weekly dosing instead of daily administration. MK-677 elevates insulin levels by 20–40% in some subjects due to its ghrelin mimetic effects—ghrelin stimulates appetite and insulin secretion simultaneously. The water retention is aldosterone-mediated (GH increases renal sodium retention), and the glucose elevation reflects insulin resistance developing over 8–12 weeks at 25 mg daily. Hexarelin produces similar GH elevation with less chronic ghrelin receptor activation, reducing metabolic side effects while maintaining anabolic outcomes.

Add enclomiphene 12.5 mg every other day to maintain LH signaling during the SARM cycle, or reduce RAD-140 to 5 mg daily and assess whether anabolic effects remain sufficient. Research from 2021 published in Andrology demonstrated that enclomiphene co-administration preserved LH levels at 80% of baseline in subjects using anabolic steroids—the same principle applies to SARMs. The enclomiphene blocks estradiol feedback at the hypothalamus, preventing the suppressive signal that RAD-140's androgenic activity would otherwise trigger. Post-cycle, discontinue the SARM and continue enclomiphene for 4 weeks to accelerate LH recovery.